Valuation dashboard for GH Research PLC (GHRS) with P/E N/A, P/B 5.14, EV/EBITDA -25.02 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD).
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $27.75, GHRS has negative trailing earnings (P/E not meaningful) and an ROE of -20.86%. Market capitalisation stands at $1.9B.
Balance sheet quality for GHRS: current ratio of 34.1. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 5.14 |
| EV / EBITDA | -25.02 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $3.99 |
| vs Current Price | -85.6% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| GHRS | GH Research PLC | $1.9B | 5.14 | -20.9% | |
| PVLA | Palvella Therapeutics, Inc. | $2.2B | 42.11 | -149.1% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.6B | 29.76 | 6.46 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% |
Price
| Price | $27.75 |
| Market Cap | $1.9B |
| Exchange | NASDAQ |
| Country | IE |
Profitability
| Return on Equity | -20.86% |
| Return on Invested Capital | -19.85% |
| Return on Assets | -16.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ABUS · KURA · LENZ · NBTX · PROK · PVLA · RZLT
Explore sector: Healthcare · Biotechnology
More sections of GHRS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks